Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Elimination

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    521 result(s) found for: Elimination. Displaying page 1 of 27.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2011-000206-22 Sponsor Protocol Number: 130101 Start Date*: 2011-04-11
    Sponsor Name:Helsingin Yliopisto, Kemian laitos
    Full Title: Elimination kinetics of HCN after inhaled exposure
    Medical condition: Healthy volunteers
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023030-23 Sponsor Protocol Number: 10076 Start Date*: 2010-12-24
    Sponsor Name:The Univeristy of Nottingham [...]
    1. The Univeristy of Nottingham
    2.
    Full Title: Circadian Rhythm In Tobramycin Elimination in Cystic Fibrosis (CRITIC) - a Randomised Pharmacokinetic Comparison of Tobramycin in CF
    Medical condition: Cystic fibrosis
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-000131-13 Sponsor Protocol Number: DDD17CRCCXB1 Start Date*: 2017-05-11
    Sponsor Name:KU Leuven
    Full Title: Pharmacokinetics of Celebrex for the prevention/treatment of colorectal cancer: Systemic pharmacokinetics and elimination of Celebrex in healthy volunteers
    Medical condition: Colorectal cancer
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2008-005438-57 Sponsor Protocol Number: HGWH0008 Start Date*: 2008-11-19
    Sponsor Name:Academic Medical Centre
    Full Title: Predictive value of drug elimination gene polymorphisms on clearance and dose adjustment of sunitinib (Sutent, SU11248) in patients with cancer
    Medical condition: The main group are patients with renal cell cancer currently being or about to be treated with sunitinib. Other diseases with efficacy of sunitinib are Gastro Intestinal Stromal cell tumour (GIST).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-005716-64 Sponsor Protocol Number: 112233020781 Start Date*: 2008-08-28
    Sponsor Name:Universitätsklinik für Psychiatrie des Kindes- und Jugendalters, AKH Wien, Medizinische Universität
    Full Title: Elevated elimination rates of quetiapine in adolescent patients with schizophrenia (ICD 10: F 20.-), bipolar affective disorder (ICD 10: F 31.-), disorders in impulse control with current PTSD (ICD...
    Medical condition: schizophrenia (ICD 10: F 20.-), bipolar affective disorder (ICD 10: F 31.-), disorders of impulse control with current PTSD (ICD 10: F 43.1) or personality disorder (ICD 10: F 60.-).
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2013-001976-39 Sponsor Protocol Number: CHDR1227 Start Date*: 2013-07-30
    Sponsor Name:Centre for Human Drug Research
    Full Title: Randomized, open-label, crossover study into the contribution of the intestines and kidney in the diurnal variation of Levofloxacin pharmacokinetics
    Medical condition: The circadian variation in the relative contribution of intestinal uptake and renal elimination of levofloxacin
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-002962-20 Sponsor Protocol Number: TMD01/2007 Start Date*: 2007-03-15
    Sponsor Name:Hannover Medical School
    Full Title: Elimination of the preleukemic clone in children with Down syndrome and transient myeloproloferative disorder (TMD) to prevent AML - Model of leukemia prevention
    Medical condition: Preleukemic clones have been frequently detected in newborns. The transient myeloproliferative disorder (TMD) represents a preleukemic clone. More than 20% of the patients developed acute megakaryo...
    Disease:
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2008-005110-41 Sponsor Protocol Number: 9999999999999999999 Start Date*: 2008-12-09
    Sponsor Name:not applicable
    Full Title: Circadian Influence on Renal Clearance of Aminoglycosides in cystic fibrosis patients
    Medical condition: Repeated or extended dosing of aminoglycosides may cause damage to the proximal tubuli, resulting in renal impairment. Renal impairment affects up to 40 % of adult CF patients, measured after estim...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-000368-10 Sponsor Protocol Number: NEX-426-MEI-0040-I Start Date*: 2006-08-10
    Sponsor Name:Tecnical University of Munich
    Full Title: High-dose therapy with Esomeprazol in combination with Baclofen therapy for symptomatic therapy-resistant gastrooesophageal reflux disease.
    Medical condition: Gastroesophageal reflux disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-002820-20 Sponsor Protocol Number: OZBS62.14078 Start Date*: 2016-02-03
    Sponsor Name:Erasmus MC Dept. Urology
    Full Title: Are alpha blockers effective in the treatment of bladder elimination problems in female patients with Multiple Sclerosis?
    Medical condition: Bladder dysfunction in Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10069632 Bladder dysfunction PT
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-004980-36 Sponsor Protocol Number: MS200527-0082 Start Date*: 2020-09-21
    Sponsor Name:Merck Healthcare KGaA
    Full Title: A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Scleros...
    Medical condition: Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PT (Prematurely Ended) LT (Completed) SK (Completed) LV (Completed) GR (Completed) BG (Completed) PL (Prematurely Ended) NO (Prematurely Ended) ES (Completed) DE (Prematurely Ended) SI (Completed) IT (Prematurely Ended) RO (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2014-000973-38 Sponsor Protocol Number: 14-026 Start Date*: 2014-05-14
    Sponsor Name:RWTH Aachen vertreten durch das CTC-A
    Full Title: Xenon-inhalation: elimination of xenon and its effect on erythropoetin-levels in blood of healthy volunteers
    Medical condition: Healthy volunteers
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-006042-39 Sponsor Protocol Number: HUN-FAVI-02 Start Date*: 2021-02-19
    Sponsor Name:Hungarian Ministry of Innovation and Technology - Representative: Hecrin Consortium
    Full Title: A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of Favipiravir-HU compared to placebo as add-on therapy to standard of care in asymptomatic to mild severity C...
    Medical condition: Patients with PCR confirmed SARS-CoV-2 infection who are asymptomatic or have mild symptoms will be enrolled
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-006964-48 Sponsor Protocol Number: 20040215 Start Date*: 2007-04-13
    Sponsor Name:Amgen Inc
    Full Title: An Open-Label, Multi-Center, Phase 2 Safety and Efficacy Study of Denosumab (AMG 162) in Subjects with Recurrent or Unresectable Giant Cell Tumor (GCT) of Bone
    Medical condition: Giant Cell Tumor (GCT) of bone
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005968 Bone giant cell tumor LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-002910-37 Sponsor Protocol Number: TEA Start Date*: 2019-10-07
    Sponsor Name:Erasmus MC
    Full Title: Study on the pharmacokinetic interaction between green tea and tamoxifen in patients with breast cancer. “the TEA study”
    Medical condition: Breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-000985-34 Sponsor Protocol Number: 001:CD40L Start Date*: 2006-06-15
    Sponsor Name:Clinical Immunology Division
    Full Title: A Phase I-IIa Study of Dose escalating Intravesical AdCD40L instillation in Urinary Bladder Carcinoma
    Medical condition: Urinary bladder cancer is an attractive target for immunostimulating gene therapy because it is sensitive for immunotherapy as demonstrated by the life-prolonging effect of bacillus Calmette-Guérin...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003053-26 Sponsor Protocol Number: TMC-BIV-05-01 Start Date*: 2005-12-08
    Sponsor Name:The Medicines Company UK Ltd
    Full Title: The ZBMUF trial: an open-label randomised study of the effects of ultra-filtration and high dose aprotinin on bivalirudin pharmacokinetics during and/or after cardiopulmonary bypass surgery
    Medical condition: This trial will involve approximately 42 patients requiring coronary artery bypass graft surgery (CABG).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-003151-62 Sponsor Protocol Number: BENOS Start Date*: 2014-10-09
    Sponsor Name:Infectopharm Arzneimittel und Consilium GmbH
    Full Title: A randomised, two-period two-stage cross-over study on the relative bioavailability of two different formulations of single doses of noscapine (phase I/IV, open-label) in healthy volunteers (fasted...
    Medical condition: healthy subjects
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-000655-41 Sponsor Protocol Number: CFTY720A2308 Start Date*: 2005-02-10
    Sponsor Name:Novartis Farmacéutica S.A
    Full Title: A one-year, multicenter, open-label, feasibility study to evaluate the safety and the efficacy of FTY720 5mg introduction and CNI elimination in adult maintenance renal transplant reicpients mainta...
    Medical condition: prevention of acute rejection in maintenance renal transplant recipients
    Disease: Version SOC Term Classification Code Term Level
    7.0 10023439 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-002012-12 Sponsor Protocol Number: BENOS-2-L Start Date*: 2021-12-13
    Sponsor Name:InfectoPharm Arzneimittel und Consilium GmbH
    Full Title: A randomised, two-period two-stage cross-over study on the relative bioavailability of two different liquid formulations of single noscapine doses (phase I/IV, open-label) in healthy volunteers (fa...
    Medical condition: Healthy controls
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 07 14:46:37 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA